Advertisement

Topics

Comments on switching in FDA’s interchangeability guidance from big pharma

03:55 EDT 23 Jun 2017 | Generics and Biosimilars Initiative

The US Food and Drug Administration’s (FDA) comment period on its guidance on the interchangeability of biosimilars with their reference biologicals ended on 19 May 2017 [1].

Original Article: Comments on switching in FDA’s interchangeability guidance from big pharma

NEXT ARTICLE

More From BioPortfolio on "Comments on switching in FDA’s interchangeability guidance from big pharma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...